Resverlogix Reschedules Update Webcast and Conference Call
January 27, 2021 17:36 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Company") (TSX:RVX) announces that it has postponed the webcast and conference call, previously...
Resverlogix Announces Update Webcast and Conference Call
January 18, 2021 07:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a...
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
January 12, 2021 08:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and...
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
December 22, 2020 17:17 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in...
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
December 22, 2020 07:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce recent published findings in the high-impact journal,...
Resverlogix Files Notice of Annual and Special Meeting of Shareholders
November 20, 2020 18:28 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and...
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
November 12, 2020 08:00 ET
|
Resverlogix Corp
Publication Explores the Beneficial Effects of Apabetalone on the Immune Cells of Diabetic Patients Event Reminder: Multiple Presentations on Apabetalone to be made during the American Heart...
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
November 02, 2020 07:30 ET
|
Resverlogix Corp
Significantly Strengthens Intellectual Property Portfolio and Apabetalone’s Commercial Runway Position Through 2040 BETonMACE Results Show Significant Improvement of Key Markers of Diabetes and Renal...
将Resverlogix临床候选药物apabetalone列为潜在新冠肺炎治疗方法（包括减少细胞因子风暴）的第二篇文章发表
October 26, 2020 12:00 ET
|
Resverlogix Corp
阿尔伯塔省卡尔加里, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下称"Resverlogix"或“公司”）（TSX:RVX）今日宣布，同行评议期刊《Medicine in Drug Discovery》（新药发现医学）发表重点介绍该公司后期临床研究候选药物apabetalone的文章，题为“新冠肺炎导致多器官受损的蛋白驱动机理”。...
Resverlogix 臨床候選藥物 Apabetalone 因具有潛在治療新型冠狀病毒 COVID-19 功效，包括減少細胞因子風暴，而在第二份出版物入圍。
October 26, 2020 12:00 ET
|
Resverlogix Corp
艾伯塔省卡爾加里, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp.（「Resverlogix」或「公司」）(TSX:RVX) 今天宣佈，其晚期臨床候選藥物 apabetalone 在同行評審期刊《Medicine in Drug Discovery》最近一篇標題為： 「Protein-driven mechanism of...